Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User hides baldness with side hair growth, others suggest it looks good but may not work in all conditions. Some recommend starting treatment or considering a hair transplant.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The conversation is about a user concerned about hair thinning despite using finasteride, minoxidil, RU58841, and recently adding dutasteride. Most responses suggest there is no noticeable difference in hair loss, attributing concerns to paranoia, and recommend continuing the current treatment or adjusting expectations.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Eli Lilly's drug baricitinib showed effectiveness in treating alopecia areata, with higher doses resulting in significant hair regrowth compared to placebo. The treatment is not for male pattern baldness.

A 21-year-old shares progress using oral dutasteride for 3 months and topical minoxidil 5% for 3 weeks, noting reduced hair shedding and new baby hairs. They seek feedback on when to expect noticeable thickening and hairline improvement.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.